Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 13, 2017 - Issue
Submit an article Journal homepage
1,704
Views
246
CrossRef citations to date
0
Altmetric
Review

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

Marco Solmi1 Neuroscience Department, University of Padua;2 Institute for Clinical Research and Education in Medicine, Padua, Italy
,
Andrea Murru3 Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
,
Isabella Pacchiarotti3 Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
,
Juan Undurraga4 Department of Psychiatry, Faculty of Medicine, Clínica Alemana Universidad del Desarrollo;5 Early Intervention Program, J. Horwitz Psychiatric Institute, Santiago, Chile
,
Nicola Veronese2 Institute for Clinical Research and Education in Medicine, Padua, Italy;6 National Research Council, Ageing Section, Padua
,
Michele Fornaro7 Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, School of Medicine, University “Federico II”, Naples, Italy;8 New York State Psychiatric Institute, Columbia University, New York, NY, USA
,
Brendon Stubbs2 Institute for Clinical Research and Education in Medicine, Padua, Italy;9 Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London;10 Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London;11 Faculty of Health, Social Care and Education, Anglia Ruskin University, Chelmsford, UK
,
Francesco Monaco2 Institute for Clinical Research and Education in Medicine, Padua, Italy
,
Eduard Vieta3 Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain
,
Mary V Seeman12 Institute of Medical Science, Toronto, ON, Canada
,
Christoph U Correll13 Department of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, Glen Oaks;14 Department of Psychiatry and Molecular Medicine Hempstead, Hofstra Northwell School of Medicine, Hempstead, NY, USA
&
André F Carvalho2 Institute for Clinical Research and Education in Medicine, Padua, Italy;15 Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, BrazilCorrespondence[email protected]
 show all
Pages 757-777 | Published online: 29 Jun 2017

Citations (246)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (25)

Hagar Abuelazm, Omar H. Elsayed & Rif S. El-Mallakh. (2023) Evaluating lumateperone for its use in treating depressive episodes associated with bipolar I or II disorder in adults. Expert Review of Neurotherapeutics 23:8, pages 751-756.
Read now
Mikkel Højlund & Christoph.U Correll. (2022) Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia. Expert Opinion on Investigational Drugs 31:12, pages 1279-1290.
Read now
Catalin Adrian Buzea, Peter Manu, Lorena Dima & Christoph U. Correll. (2022) Drug–drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs. Expert Opinion on Drug Metabolism & Toxicology 18:11, pages 729-744.
Read now
Petter A. Ringen, Elisabeth Lund-Stenvold, Ole A. Andreassen, Torfinn L. Gaarden, Cecilie B. Hartberg, Erik Johnsen, Silje Myklatun, Kåre Osnes, Kirsten Sørensen, Kjetil Sørensen, Arne Vaaler, Serena Tonstad, John A. Engh & Anne Høye. (2022) Quality of clinical management of cardiometabolic risk factors in patients with severe mental illness in a specialist mental health care setting. Nordic Journal of Psychiatry 76:8, pages 602-609.
Read now
Tommaso B. Jannini, Andrea Sansone, Rodolfo Rossi, Giorgio Di Lorenzo, Massimiliano Toscano, Alberto Siracusano & Emmanuele A. Jannini. (2022) Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment. Expert Opinion on Pharmacotherapy 23:9, pages 1065-1080.
Read now
Catalin Adrian Buzea, Lorena Dima, Christoph U. Correll & Peter Manu. (2022) Drug–drug interactions involving antipsychotics and antihypertensives. Expert Opinion on Drug Metabolism & Toxicology 18:4, pages 285-298.
Read now
Meghan L. McPhie & Mark G. Kirchhof. (2022) A systematic review of antipsychotic agents for primary delusional infestation. Journal of Dermatological Treatment 33:2, pages 709-721.
Read now
Ágota Barabássy, Barbara Sebe, Károly Acsai, István Laszlovszky, Balázs Szatmári, Willie R Earley & György Németh. (2021) Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatric Disease and Treatment 17, pages 957-970.
Read now
Enrico Capuzzi, Alice Caldiroli, Veronica Ciscato, Stefania Russo & Massimiliano Buoli. (2021) Experimental Serotonergic Agents for the Treatment of Schizophrenia. Journal of Experimental Pharmacology 13, pages 49-67.
Read now
Fayçal Mouaffak, Florian Ferreri, Julie Bourgin-Duchesnay, Emmanuelle Baloche, Olivier Blin, Pierre Vandel, Ricardo P. Garay, Pierre Vidailhet, Emmanuelle Corruble & Pierre-Michel Llorca. (2021) Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. Expert Opinion on Pharmacotherapy 22:18, pages 2507-2519.
Read now
Piotr Stępnicki, Magda Kondej, Oliwia Koszła, Justyna Żuk & Agnieszka A. Kaczor. (2021) Multi-targeted drug design strategies for the treatment of schizophrenia. Expert Opinion on Drug Discovery 16:1, pages 101-114.
Read now
Jakub Trawiński, Ewelina Kozioł & Robert Skibiński. (2020) Influence of the UV–Vis irradiation on the acute toxicity to zebrafish and mutagenicity of the selected psychotropic drugs. Journal of Environmental Science and Health, Part A 55:14, pages 1624-1637.
Read now
Ajay Nair, Amanie Salem, Anna-Lee Asamoah, Ravipreet Gosal & George T Grossberg. (2020) An update on the efficacy and safety of iloperidone as a schizophrenia therapy. Expert Opinion on Pharmacotherapy 21:15, pages 1793-1798.
Read now
Akhil Suresh, Reema Narayan & Usha Y Nayak. (2020) Recent advances in the development of asenapine formulations. Expert Opinion on Drug Delivery 17:10, pages 1377-1393.
Read now
Laura Orsolini, Domenico De Berardis & Umberto Volpe. (2020) Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opinion on Drug Safety 19:8, pages 981-998.
Read now
Hanne Høilund, David P. Galea & Petter Andreas Ringen. (2020) Improving quality of antipsychotic polypharmacy: a pilot study. Nordic Journal of Psychiatry 74:3, pages 208-212.
Read now
Katie M Rieck, Sandeep Pagali & Donna M Miller. (2020) Delirium in hospitalized older adults. Hospital Practice 48:sup1, pages 3-16.
Read now
Giancarlo Cerveri, Camilla Gesi & Claudio Mencacci. (2019) Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatric Disease and Treatment 15, pages 1525-1535.
Read now
Michele Fornaro, Andrea Fusco, Annalisa Anastasia, Carlo Ignazio Cattaneo & Domenico De Berardis. (2019) Brexpiprazole for treatment-resistant major depressive disorder. Expert Opinion on Pharmacotherapy 20:16, pages 1925-1933.
Read now
Nazan Aydın, Hasan Mervan Aytaç, Esra Yazıcı, Doğan Yılmaz, Pınar Çetinay Aydın, Gökşen Yüksel Yalçın, Yücel Kadıoğlu, Cana Canbay, Merve Terzioğlu, Onur Şenol, Cavide Çakmak & Aysel Özer. (2019) Rediscovery of penicillin of psychiatry: haloperidol decanoate. Psychiatry and Clinical Psychopharmacology 29:3, pages 264-275.
Read now
Marco Solmi, Giorgio Pigato, John M Kane & Christoph U Correll. (2018) Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Design, Development and Therapy 12, pages 1215-1238.
Read now
John W. Newcomer, Hans Eriksson, Peter Zhang, Emmanuelle Weiller & Catherine Weiss. (2018) Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. Current Medical Research and Opinion 34:12, pages 2197-2205.
Read now
Alexandre González-Rodríguez & Mary V. Seeman. (2018) Pharmacotherapy for schizophrenia in postmenopausal women. Expert Opinion on Pharmacotherapy 19:8, pages 809-821.
Read now
Michele Fornaro, Lubna Kardash, Stefano Novello, Andrea Fusco, Annalisa Anastasia, Domenico De Berardis, Giampaolo Perna & Mauro Giovanni Carta. (2018) Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective. Expert Opinion on Drug Discovery 13:3, pages 221-228.
Read now
H. Bashir & J. Jankovic. (2018) Treatment options for chorea. Expert Review of Neurotherapeutics 18:1, pages 51-63.
Read now

Articles from other publishers (221)

Mahsa Mohammadi, Kiarash Eskandari, Ronak Azizbeigi & Abbas Haghparast. (2023) The inhibitory effect of cannabidiol on the rewarding properties of methamphetamine in part mediates by interacting with the hippocampal D1-like dopamine receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry 126, pages 110778.
Crossref
Wujie Ye, Jingyu Xing, Zekai Yu, Xingang Hu & Yan Zhao. (2023) Mechanism and treatments of antipsychotic-induced weight gain. International Journal of Obesity 47:6, pages 423-433.
Crossref
Joshua T Kantrowitz, Christoph U Correll, Rakesh Jain & Andrew J Cutler. (2023) New Developments in the Treatment of Schizophrenia: An Expert Roundtable. International Journal of Neuropsychopharmacology 26:5, pages 322-330.
Crossref
Felice Iasevoli, Camilla Avagliano, Luigi D’Ambrosio, Annarita Barone, Mariateresa Ciccarelli, Giuseppe De Simone, Benedetta Mazza, Licia Vellucci & Andrea de Bartolomeis. (2023) Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal. Biomedicines 11:3, pages 895.
Crossref
Roger S. McIntyre, Suresh Durgam, Susan G. Kozauer, Richard Chen, Jason Huo, Robert E. Davis & Andrew J. Cutler. (2023) The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses. European Neuropsychopharmacology 68, pages 78-88.
Crossref
Trisha Suppes, Suresh Durgam, Susan G. Kozauer, Richard Chen, Hassan D. Lakkis, Robert E. Davis, Andrew Satlin, Kimberly E. Vanover, Sharon Mates, Roger S. McIntyre & Mauricio Tohen. (2023) Adjunctive lumateperone ( ITI ‐007) in the treatment of bipolar depression: Results from a randomized placebo‐controlled clinical trial . Bipolar Disorders.
Crossref
Adriana Stelmach, Katarzyna Guzek, Alicja Rożnowska, Irena Najbar & Anna Sadakierska-Chudy. (2022) Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms. Pharmacological Reports 75:1, pages 19-31.
Crossref
Mohita JoshiSujita Kumar Kar. (2023) Allergic Cutaneous Drug Eruptions with Quetiapine: A Case Study. Indian Journal of Psychological Medicine, pages 025371762211489.
Crossref
Anna Partyka, Katarzyna Górecka, Joanna Gdula-Argasińska, Natalia Wilczyńska-Zawal, Magdalena Jastrzębska-Więsek & Anna Wesołowska. (2023) Selective 5-HT6 Receptor Ligands (Agonist and Antagonist) Show Different Effects on Antipsychotic Drug-Induced Metabolic Dysfunctions in Rats. Pharmaceuticals 16:2, pages 154.
Crossref
Marco Solmi, Markku Lähteenvuo, Christoph U Correll, Antti Tanskanen, Jari Tiihonen & Heidi Taipale. (2023) Antipsychotic Use and Risk of Low-Energy Fractures in People With Schizophrenia: A Nationwide Nested Case-Control Study in Finland. Schizophrenia Bulletin 49:1, pages 78-89.
Crossref
Giovanni Croatto, Davy Vancampfort, Alessandro Miola, Miriam Olivola, Jess G. Fiedorowicz, Joseph Firth, Ovidiu Alexinschi, Marcel A. Gaina, Vladimir Makkai, Fernanda Cunha Soares, Leandro Cavaliere, Giorgia Vianello, Brendon Stubbs, Paolo Fusar-Poli, Andre F. Carvalho, Eduard Vieta, Samuele Cortese, Jae Il Shin, Christoph U. Correll & Marco Solmi. (2022) The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials. Molecular Psychiatry 28:1, pages 369-390.
Crossref
Sophia Anagnostis, Nimrat Khehra & Mayur S. Parmar. 2023. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Nimra Mumtaz & Muhammad Omair Hassan. 2023. Cognizance of Schizophrenia:: A Profound Insight into the Psyche. Cognizance of Schizophrenia:: A Profound Insight into the Psyche 127 147 .
Steffen Moritz, Eva Carolin Krieger, Francesca Bohn, Julia Elmers & Ruth VeckenstedtSteffen Moritz, Eva Carolin Krieger, Francesca Bohn, Julia Elmers & Ruth Veckenstedt. 2023. MKT+. MKT+ 9 57 .
Scott L. Zeller, Michael P. Wilson & Bruno Pacciardi. 2020. Tasman’s Psychiatry. Tasman’s Psychiatry 1 17 .
Andrea de Bartolomeis, Giuseppe De Simone, Mariateresa Ciccarelli, Alessia Castiello, Benedetta Mazza, Licia Vellucci & Annarita Barone. (2022) Antipsychotics-Induced Changes in Synaptic Architecture and Functional Connectivity: Translational Implications for Treatment Response and Resistance. Biomedicines 10:12, pages 3183.
Crossref
Christoph U. Correll, Angel S. Angelov, Andrew C. Miller, Peter J. Weiden & Stephen K. Brannan. (2022) Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia 8:1.
Crossref
Michael J. Doane, Leona Bessonova, Haley S. Friedler, Kathleen M. Mortimer, Harry Cheng, Thomas Brecht, Amy K. O’Sullivan, Hannah Cummings, David McDonnell & Jonathan M. Meyer. (2022) Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry 22:1.
Crossref
Marco SolmiHeidi TaipaleMinna HolmAntti TanskanenEllenor Mittendorfer-RutzChristoph U. CorrellJari Tiihonen. (2022) Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis. American Journal of Psychiatry 179:12, pages 938-946.
Crossref
Sandra M. Christensen, Catherine Varney, Vivek Gupta, Lori Wenz & Harold Edward Bays. (2022) Stress, psychiatric disease, and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 4, pages 100041.
Crossref
Francesco Bartoli, Bianca Bachi, Angela Calabrese, Riccardo Matteo Cioni, Pierluca Guzzi, Christian Nasti, Dario Palpella, Filippo Fabio Barbieri, Serena Limonta, Cristina Crocamo & Giuseppe Carrà. (2022) Effect of long-acting injectable antipsychotics on emergency department visits and hospital admissions in people with bipolar disorder: A retrospective mirror-image analysis from the Northern Milan Area Cohort (NOMIAC) study. Journal of Affective Disorders 318, pages 88-93.
Crossref
John H Krystal, John M Kane, Christoph U Correll, David P Walling, Matthew Leoni, Sridhar Duvvuri, Shrinal Patel, Ih Chang, Philip Iredale, Lillian Frohlich, Stacey Versavel, Pamela Perry, Raymond Sanchez & John Renger. (2022) Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. The Lancet 400:10369, pages 2210-2220.
Crossref
Rui Bai, Xiaohui Dai, Xingang Miao, Bing Xie, Feng Yu, Bin Cong, Di Wen & Chunling Ma. (2022) Dynamic Changes in Plasma Metabolic Profiles Reveal a Potential Metabolite Panel for Interpretation of Fatal Intoxication by Chlorpromazine or Olanzapine in Mice. Metabolites 12:12, pages 1184.
Crossref
Hiroyuki Kamei. (2022) Polypharmacy Management of Antipsychotics in Patients with Schizophrenia. Medicina 58:11, pages 1584.
Crossref
Syed Nasir Abbas Bukhari. (2022) Consequences of Antipsychotic Medications on Mental Health. Current Drug Safety 17:4, pages 285-293.
Crossref
Laura A. Bajor, Charmi Balsara & David N. Osser. (2022) An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update. Psychiatry Research 317, pages 114840.
Crossref
Gillian Gonzales, Kari Tornes & Stephen R. Saklad. (2022) Stewardship applied to antipsychotics: Development of an antipsychotic stewardship program in inpatient settings for monitoring and optimizing outcomes. Mental Health Clinician 12:5, pages 320-326.
Crossref
Lijuan Li, Xiaohu Liu, Yunxia Cui, Yang Chen, Huiwen Wu, Jing Wang, Xiaodi Gong, Xiaoyan Gao, Linlin Yang, Jian Li, Xiao Sun, Fei Mao & Yudong Wang. (2022) Novel chlorpromazine derivatives as anti-endometrial carcinoma agents with reduced extrapyramidal side effects. Bioorganic Chemistry 127, pages 106008.
Crossref
Mikkel Højlund, Kjeld Andersen, Martin T. Ernst, Christoph U. Correll & Jesper Hallas. (2022) Use of low‐dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator‐controlled cohort study. World Psychiatry 21:3, pages 444-451.
Crossref
Maite Arribas, Marco Solmi, Trevor Thompson, Dominic Oliver & Paolo Fusar-Poli. (2022) Timing of antipsychotics and benzodiazepine initiation during a first episode of psychosis impacts clinical outcomes: Electronic health record cohort study. Frontiers in Psychiatry 13.
Crossref
Alexandre González-Rodríguez, José Antonio Monreal, Mentxu Natividad & Mary V. Seeman. (2022) Collaboration between Psychiatrists and Other Allied Medical Specialists for the Treatment of Delusional Disorders. Healthcare 10:9, pages 1729.
Crossref
Eszter Fliszár-Nyúl, Rita Csepregi, Gábor Benkovics, Lajos Szente & Miklós Poór. (2022) Testing the Protective Effects of Sulfobutylether-Βeta-Cyclodextrin (SBECD) and Sugammadex against Chlorpromazine-Induced Acute Toxicity in SH-SY5Y Cell Line and in NMRI Mice. Pharmaceutics 14:9, pages 1888.
Crossref
Mikkel Højlund, Lotte Rasmussen, Morten Olesen, Trine Munk‐Olsen & Anton Pottegård. (2022) Who prescribes quetiapine in Denmark?. British Journal of Clinical Pharmacology 88:9, pages 4224-4229.
Crossref
Marco Solmi & Christoph U Correll. (2022) The antipsychotic paradox: Lessons regarding determinants of premature mortality. European Neuropsychopharmacology 62, pages 1-3.
Crossref
Johannes Heck, Christian Ihlefeld, Olaf Krause, Dirk O. Stichtenoth, Martin Schulze Westhoff, Nina Noltemeyer, Kirsten Jahn, Lea Prost, Swetlana Gerbel, Martin Klietz, Stefan Bleich, Helge Frieling & Adrian Groh. (2022) Medication‐related problems in geriatric psychiatry—a retrospective cohort study. International Journal of Geriatric Psychiatry 37:9.
Crossref
Giulia M. Giordano, Francesco Brando, Pasquale Pezzella, Maria De Angelis, Armida Mucci & Silvana Galderisi. (2022) Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature. Frontiers in Psychiatry 13.
Crossref
Giovanni Martinotti, Stefania Chiappini, Alessio Mosca, Andrea Miuli, Maria Chiara Santovito, Mauro Pettorruso, Valentin Skryabin, Stefano L. Sensi & Massimo Di Giannantonio. (2022) Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice. Current Pharmaceutical Design 28:27, pages 2241-2259.
Crossref
K. Y. Kalitin, G. V. Pridvorov, A. A. Spasov & O. Y. Mukha. (2022) Effect of Clozapine and 5-NT2A-Antagonist RU-31 on electroencephalography and Motor Activity of Rats in a Model of Schizophrenia with Neonatal Destruction of the Ventral Hippocampus. Kuban Scientific Medical Bulletin 29:5, pages 108-122.
Crossref
Alessandro Rodolico, Carmen Concerto, Alessia Ciancio, Spyridon Siafis, Laura Fusar-Poli, Carla Romano, Elisa Scavo, Antonino Petralia, Salvatore Salomone, Maria Signorelli, Stefan Leucht & Eugenio Aguglia. (2022) Validation of the Glasgow Antipsychotic Side-Effect Scale (GASS) in an Italian Sample of Patients with Stable Schizophrenia and Bipolar Spectrum Disorders. Brain Sciences 12:7, pages 891.
Crossref
Juan D Duque-Yemail & Juan Carlos Avila. (2022) Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series. Neuropsychiatric Disease and Treatment Volume 18, pages 1433-1440.
Crossref
Kevin W. Cahill & Frederick Giberson. 2022. Surgical Critical Care and Emergency Surgery. Surgical Critical Care and Emergency Surgery 203 211 .
Heidi Taipale, Antti Tanskanen, Jurjen J Luykx, Marco Solmi, Stefan Leucht, Christoph U Correll & Jari Tiihonen. (2022) Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. Schizophrenia Bulletin 48:4, pages 774-784.
Crossref
Diane Merino, Arnaud Fernandez, Alexandre O. Gérard, Nouha Ben Othman, Fanny Rocher, Florence Askenazy, Céline Verstuyft, Milou-Daniel Drici & Susanne Thümmler. (2022) Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review. Pharmaceuticals 15:6, pages 749.
Crossref
Christoph U. Correll, Marco Solmi, Giovanni Croatto, Lynne Kolton Schneider, S. Christy Rohani‐Montez, Leanne Fairley, Nathalie Smith, István Bitter, Philip Gorwood, Heidi Taipale & Jari Tiihonen. (2022) Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors. World Psychiatry 21:2, pages 248-271.
Crossref
Giovanni Ostuzzi, Federico Bertolini, Federico Tedeschi, Giovanni Vita, Paolo Brambilla, Lorenzo Fabro, Chiara Gastaldon, Davide Papola, Marianna Purgato, Guido Nosari, Cinzia Del Giovane, Christoph U. Correll & Corrado Barbui. (2022) Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants. World Psychiatry 21:2, pages 295-307.
Crossref
Deepan Singh, Emily Mozdzer & Aaron Pinkhasov. 2022. Neuro-behavioral Manifestations of Prader-Willi Syndrome. Neuro-behavioral Manifestations of Prader-Willi Syndrome 116 144 .
Deepan Singh & Emily Mozdzer. 2022. Neuro-behavioral Manifestations of Prader-Willi Syndrome. Neuro-behavioral Manifestations of Prader-Willi Syndrome 41 57 .
Nicholas Comardelle, Amber Edinoff & Juliana Fort. (2022) Delusions of Glass Under Skin: An Unusual Case of Somatic-Type Delusional Disorder Treated with Olanzapine. Health Psychology Research 10:2.
Crossref
Robert Sotille, Herpreet Singh, Anne Weisman & Thomas Vida. (2022) Unraveling the Mysteries of Mental Illness With Psilocybin. Cureus.
Crossref
Larry Culpepper, Eduard Vieta, Deanna L Kelly, Mehul D Patel, Balázs Szatmári, Arlene Hankinson & Willie R Earley. (2022) Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. Neuropsychiatric Disease and Treatment Volume 18, pages 995-1011.
Crossref
Jennifer Fontaine, Evelyn Chin, Jean-François Provencher, Anthony Rainone, Dana Wazzan, Carmella Roy, Soham Rej, Marie Lordkipanidze & Vincent Dagenais-Beaulé. (2022) Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study. BMJ Open 12:4, pages e055454.
Crossref
Brayden Kameg & Claire Champion. (2021) Atypical antipsychotics: Managing adverse effects. Perspectives in Psychiatric Care 58:2, pages 691-695.
Crossref
Mikkel Højlund, Christina Blanner Wagner, Rikke Wesselhoeft, Kjeld Andersen, Anders Fink‐Jensen & Jesper Hallas. (2022) Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study. Basic & Clinical Pharmacology & Toxicology 130:4, pages 501-512.
Crossref
Maria Soto-Martin, Erin P. Foff & Davangere P. Devanand. (2022) Relapse in Dementia-related Psychosis and Clinical Decisions. Alzheimer Disease & Associated Disorders 36:2, pages 180-184.
Crossref
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Pablo-Emilio Verde, Christoph U Correll, Michael Kluge, Christian Makiol, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Berthold Langguth, Timm B Poeppl, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Gerhard Gründer, Alkomiet Hasan, Anke Brockhaus-Dumke, Markus Jäger, Jessica Baumgärtner, Stefan Leucht, Joachim Cordes, Christian Schmidt-Kraepelin, Joachim Cordes, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Wolfgang Gaebel, Martina Deiß, Natalia Sofie, Viktoria Galuba, Frank Wiechmann, Birgit Janssen, Michael Kluge, Christian Makiol, Lisa Kertzscher, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Anna Becker, Sandra Muszinski, Gerhard Gründer, Berthold Langguth, Timm Poeppl, Elmar Frank, Peter Kreuzer, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Tanja Veselinovic, Alkomiet Hasan, Peter Falkai, Elias Wagner, Anke Brockhaus-Dumke, Bettina Klos, Markus Jäger, Fabian Lang, Paulo Kling-Lourenço, Jessica Baumgärtner, Alkomiet Hasan, Nadine Dreimüller, Christoph Hiemke, Stefan Leucht, Stephan Heres, Claudia Leucht, Hans-Jörg Assion, Bernhard Kis, David Zilles-Wegner, Kai Kahl, Christoph Correll, Pablo-Emilio Verde, Henrike Kolbe & Anika Rottmann. (2022) Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. The Lancet Psychiatry 9:4, pages 291-306.
Crossref
Justin Di Lu, Ryan D Gotesman, Shawn Varghese, Patrick Fleming & Charles W Lynde. (2022) Treatments for Primary Delusional Infestation: Systematic Review. JMIR Dermatology 5:1, pages e34323.
Crossref
Rami Alsabbagh & Aviv Ouanounou. (2022) Burning Mouth Syndrome: Etiology, clinical presentations, and treatment alternatives. Dentistry Review 2:1, pages 100036.
Crossref
Alessandro Miola, Michele Fornaro, Fabio Sambataro & Marco Solmi. (2021) Melatonin and melatonin‐agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta‐analysis. Human Psychopharmacology: Clinical and Experimental 37:2.
Crossref
Elena Marcos-Vadillo, Lorena Carrascal-Laso, Ignacio Ramos-Gallego, Andrea Gaedigk, Belén García-Berrocal, Eduardo Mayor-Toranzo, Alfonso Sevillano-Jiménez, Almudena Sánchez, María Isidoro-García & Manuel Franco-Martín. (2022) Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a New CYP2D6 Genotype. Frontiers in Psychiatry 12.
Crossref
Peter Phiri, Tomas Engelthaler, Hannah Carr, Gayathri Delanerolle, Clive Holmes & Shanaya Rathod. (2022) Associated mortality risk of atypical antipsychotic medication in individuals with dementia. World Journal of Psychiatry 12:2, pages 306-316.
Crossref
Peter Phiri, Tomas Engelthaler, Hannah Carr, Gayathri Delanerolle, Clive Holmes & Shanaya Rathod. (2022) Associated mortality risk of atypical antipsychotic medication in individuals with dementia. World Journal of Psychiatry 12:2, pages 298-307.
Crossref
Samuel J. Millard, Carrie E. Bearden, Katherine H. Karlsgodt & Melissa J. Sharpe. (2021) The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity. Neuropsychopharmacology 47:3, pages 628-640.
Crossref
Marco Solmi, Jari Tiihonen, Markku Lähteenvuo, Antti Tanskanen, Christoph U Correll & Heidi Taipale. (2022) Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. Schizophrenia Bulletin 48:1, pages 166-175.
Crossref
Elmars Rancans, Zsófia Borbála Dombi & Ágota Barabássy. (2022) Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia. Frontiers in Psychiatry 12.
Crossref
Won Kim, Won-Myong Bahk, Young Sup Woo, Jong-Hyun Jeong, Jeong Seok Seo, IL Han Choo, Chan-Mo Yang, Jung Goo Lee, Se-Hoon Shim, Myung Hun Jung, Duk-In Jon, Sung-Yong Park, InKi Sohn, Moon-Doo Kim & Bo-Hyun Yoon. (2022) Korean Medication Algorithm Project for Bipolar Disorder 2022: Overview. Journal of Korean Neuropsychiatric Association 61:2, pages 98.
Crossref
Christoph U. Correll, Michael Tocco, Jay Hsu, Robert Goldman & Andrei Pikalov. (2022) Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia. European Psychiatry 65:1.
Crossref
Yun TienHsiang-Ping HuangDing-Lieh LiaoShang-Chien Huang. (2022) Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan. Therapeutic Advances in Psychopharmacology 12, pages 204512532211132.
Crossref
Jun Ishigooka, Kazuyuki Nakagome, Tetsuro Ohmori, Nakao Iwata, Ken Inada, Jun‐ichi Iga, Taro Kishi, Kiyoshi Fujita, Yuka Kikuchi, Toshiaki Shichijo, Hideaki Tabuse, Shotatsu Koretsune, Hiroshi Terada, Haruko Terada, Toshifumi Kishimoto, Yuichiro Tsutsumi, Yoshiki Kanda, Kazutaka Ohi & Kanji Sekiyama. (2021) Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs , a randomized, open‐label study . Psychiatry and Clinical Neurosciences 76:1, pages 22-31.
Crossref
Yamini J. Howe, Robyn P. Thom, Erin E. Notson, Christopher J. McDougle & Michelle L. Palumbo. (2022) Buspirone for the Treatment of Generalized Anxiety Disorder in Down Syndrome: 3 Cases. Journal of Developmental & Behavioral Pediatrics 43:1, pages 38-43.
Crossref
Stefania Chiappini, Alessio Mosca, Giovanni Martinotti, Francesco Di Carlo, Andrea Miuli, Luigi Dattoli, Mauro Pettorruso & Massimo Di Giannantonio. (2022) Brexpiprazole as a new approach of treatment in somatization disorder. Emerging Trends in Drugs, Addictions, and Health 2, pages 100031.
Crossref
K. Y. Kalitin, A. A. Spasov, O. Y. Mukha, G. V. Pridvorov & V. A. Lipatov. (2022) Pharmacological Targets and Mechanisms of Action of Antipsychotic Substances in the Context of the Neurochemical Theory of the Pathogenesis of Schizophrenia. Neuroscience and Behavioral Physiology 52:1, pages 108-123.
Crossref
Sulaiman Alhifzi, Nevin Zaki & Ahmed S. BaHammam. 2022. Sleep and Neuropsychiatric Disorders. Sleep and Neuropsychiatric Disorders 235 253 .
Stefano Berloffa, Claudia Dosi, Benedetta Tascini, Beatrice Fossati, Ilaria Lupetti & Gabriele Masi. (2021) Neuroleptic Malignant Syndrome in Children with Autism Spectrum Disorder (ASD): A Case Report and Brief Review of Recent Literature. Children 8:12, pages 1201.
Crossref
Ricardo Coentre, Rodrigo Saraiva, Carolina Sereijo & Pedro Levy. (2021) Cariprazine Use in Early Psychosis: Three Case Reports. Frontiers in Psychiatry 12.
Crossref
Joseph R. CalabreseSuresh DurgamAndrew SatlinKimberly E. VanoverRobert E. DavisRichard ChenSusan G. KozauerSharon MatesGary S. Sachs. (2021) Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. American Journal of Psychiatry 178:12, pages 1098-1106.
Crossref
Konstantinos N. Fountoulakis, Hans-Jurgen Moeller, Siegfried Kasper, Carol Tamminga, Shigeto Yamawaki, Rene Kahn, Rajiv Tandon, Christoph U. Correll & Afzal Javed. (2020) The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectrums 26:6, pages 562-586.
Crossref
Renato de Filippis, Daniel Guinart, Marianna Rania, Elvira Anna Carbone, Raffaele Gaetano & Cristina Segura-Garcia. (2021) Olanzapine-Related Somnambulism. Journal of Clinical Psychopharmacology 41:6, pages 658-666.
Crossref
Mayasah Al-Nema, Anand Gaurav, Vannajan Sanghiran Lee, Baskaran Gunasekaran, Ming Tatt Lee & Patrick Okechukwu. (2021) Identification of dual inhibitor of phosphodiesterase 1B/10A using structure-based drug design approach. Journal of Molecular Liquids 342, pages 117485.
Crossref
John M. Kane, Joseph P. McEvoy, Christoph U. Correll & Pierre-Michel Llorca. (2021) Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 35:11, pages 1189-1205.
Crossref
Matej Ľupták, Zdeněk Fišar & Jana Hroudová. (2021) Effect of Novel Antipsychotics on Energy Metabolism — In Vitro Study in Pig Brain Mitochondria. Molecular Neurobiology 58:11, pages 5548-5563.
Crossref
Tzu-Pei Yeh, Li-Chi Huang, Yu-Fen Chen & Jui-Fen Cheng. (2021) The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia. Healthcare 9:11, pages 1480.
Crossref
Andrea Amerio, Costanza Giacomini, Laura Fusar-Poli, Andrea Aguglia, Alessandra Costanza, Gianluca Serafini, Eugenio Aguglia & Mario Amore. (2021) Efficacy and Safety of Lurasidone in Children and Adolescents: Recommendations for Clinical Management and Future Research. Current Pharmaceutical Design 27:39, pages 4062-4069.
Crossref
Yoshiki Shionoya, Eishi Nakamura, Gentaro Tsujimoto, Takayuki Koyata, Asako Yasuda, Kiminari Nakamura & Katsuhisa Sunada. (2021) Hemodynamic Impact of Drug Interactions With Epinephrine and Antipsychotics Under General Anesthesia With Propofol. Anesthesia Progress 68:3, pages 141-145.
Crossref
Heidi Taipale, Marco Solmi, Markku Lähteenvuo, Antti Tanskanen, Christoph U Correll & Jari Tiihonen. (2021) Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. The Lancet Psychiatry 8:10, pages 883-891.
Crossref
Marco SolmiJess FiedorowiczLaura PoddigheMarco DeloguAlessandro MiolaAnne HøyeIna H. HeibergBrendon StubbsLee SmithHenrik LarssonRubina AttarRené E. NielsenSamuele CorteseJae Il ShinPaolo Fusar-PoliJoseph FirthLakshmi N. YathamAndre F. CarvalhoDavid J. CastleMary V. SeemanChristoph U. Correll. (2021) Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies. American Journal of Psychiatry 178:9, pages 793-803.
Crossref
John M Kane, Suresh Durgam, Andrew Satlin, Kimberly E Vanover, Richard Chen, Robert Davis & Sharon Mates. (2021) Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. International Clinical Psychopharmacology 36:5, pages 244-250.
Crossref
Xieguo Yan, Shiqiang Wang & Kaoxiang Sun. (2021) Long-Acting Risperidone Dual Control System: Preparation, Characterization and Evaluation In Vitro and In Vivo. Pharmaceutics 13:8, pages 1210.
Crossref
Abdullah Almotayri, Jency Thomas, Mihiri Munasinghe, Maneka Weerasinghe, Deniz Heydarian & Markandeya Jois. (2021) Metabolic and behavioral effects of olanzapine and fluoxetine on the model organism Caenorhabditis elegans. Saudi Pharmaceutical Journal 29:8, pages 917-929.
Crossref
Jennifer Erley, Sarah Goldsborough, Amy VandenBerg & Alexandra Audu. (2021) Loxapine in patient with clozapine-resistant psychosis. Mental Health Clinician 11:4, pages 263-266.
Crossref
Bayan Abdulhaq, Latefa A. Dardas & Omar Sami. (2020) Monitoring for the metabolic side effects of second‐generation antipsychotic medications: Psychiatrists' views and practices. Perspectives in Psychiatric Care 57:3, pages 1237-1243.
Crossref
Palmiero Monteleone, Giammarco Cascino, Alessio Maria Monteleone, Paola Rocca, Alessandro Rossi, Alessandro Bertolino, Eugenio Aguglia, Mario Amore, Enrico Collantoni, Giulio Corrivetti, Alessandro Cuomo, Antonello Bellomo, Enrico D’Ambrosio, Liliana Dell’Osso, Marianna Frascarelli, Giulia Maria Giordano, Luigi Giuliani, Carlo Marchesi, Cristiana Montemagni, Lucio Oldani, Federica Pinna, Maurizio Pompili, Rita Roncone, Rodolfo Rossi, Alberto Siracusano, Antonio Vita, Patrizia Zeppegno, Silvana Galderisi & Mario Maj. (2021) Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the “real-life”. Progress in Neuro-Psychopharmacology and Biological Psychiatry 109, pages 110250.
Crossref
István Laszlovszky, Ágota Barabássy & György Németh. (2021) Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Advances in Therapy 38:7, pages 3652-3673.
Crossref
Annalisa Traverso, Caterina Ancora, Silvia Zanato, Alessia Raffagnato & Michela Gatta. (2021) Diagnostic and Therapeutic Challenges of Catatonia in an Adolescent With High Functioning Autism Spectrum Disorder: A Case Report. Frontiers in Psychiatry 12.
Crossref
Liwei L. Hua, Elizabeth M. Alderman, Richard J. Chung, Laura K. Grubb, Janet Lee, Makia E. Powers, Krishna K. Upadhya & Stephenie B. Wallace. (2021) Collaborative Care in the Identification and Management of Psychosis in Adolescents and Young Adults. Pediatrics 147:6.
Crossref
Young-A Heo. (2021) Asenapine transdermal delivery system (Secuado®) in schizophrenia: a profile of its use in the USA. Drugs & Therapy Perspectives 37:6, pages 229-235.
Crossref
Bernhard Weidle, Tord Ivarsson, Fernando R. Asbahr, Rosa Calvo, David Mataix-Cols, Moira A. Rynn & Eric A. Storch. (2021) Specialty knowledge and competency standards for pharmacotherapy for pediatric obsessive-compulsive disorder. Psychiatry Research 299, pages 113858.
Crossref
Caitlin McArthur, George Ioannidis, Micaela Jantzi, Loretta Hillier, Jonathan D. Adachi, Lora Giangregorio, John Hirdes & Alexandra Papaioannou. (2021) Factors That Predict 1-Year Incident Hip and Non-Hip Fractures for Home Care Recipients: A Linked-Data Retrospective Cohort Study. Journal of the American Medical Directors Association 22:5, pages 1035-1042.
Crossref
Felipe V. Gomes & Anthony A. Grace. (2021) Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention. International Journal of Molecular Sciences 22:9, pages 4467.
Crossref
Marco Solmi, Alessandro Miola, Giovanni Croatto, Giorgio Pigato, Angela Favaro, Michele Fornaro, Michael Berk, Lee Smith, Joao Quevedo, Michael Maes, Christoph U. Correll & André F. Carvalho. (2021) How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Brazilian Journal of Psychiatry 43:2, pages 189-202.
Crossref
Mark R. Libowitz & Erika L. Nurmi. (2021) The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children. Frontiers in Psychiatry 12.
Crossref
Hitoshi Sakurai, Norio Yasui-Furukori, Takefumi Suzuki, Hiroyuki Uchida, Hajime Baba, Koichiro Watanabe, Ken Inada, Yuka Sugawara Kikuchi, Toshiaki Kikuchi, Asuka Katsuki, Ikuko Kishida & Masaki Kato. (2021) Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Pharmacopsychiatry 54:02, pages 60-67.
Crossref
Domenico De Berardis, Sergio De Filippis, Gabriele Masi, Stefano Vicari & Alessandro Zuddas. (2021) A Neurodevelopment Approach for a Transitional Model of Early Onset Schizophrenia. Brain Sciences 11:2, pages 275.
Crossref
Michele Fornaro. (2021) There are no “side” effects, just “core” effects of antipsychotic pharmacotherapy. Acta Psychiatrica Scandinavica 143:2, pages 99-100.
Crossref
Stephen M. Stahl, Sireena Sy & Gerald A. Maguire. (2020) How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice. Acta Psychiatrica Scandinavica 143:2, pages 172-180.
Crossref
Christoph U. Correll, Kimberly E. Vanover, Robert E. Davis, Richard Chen, Andrew Satlin & Sharon Mates. (2021) Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophrenia Research 228, pages 198-205.
Crossref
Heidi N. Boyda, Ric M. Procyshyn, Lurdes Tse, Jessica W. Y. Yuen, William G. Honer & Alasdair M. Barr. (2021) A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. PLOS ONE 16:1, pages e0246211.
Crossref
Alexandre González-Rodríguez, Mary V. Seeman, Aida Álvarez, Armand Guàrdia, Nadia Sanz, Genís F. Fucho, Diego J. Palao & Javier Labad. (2021) Care for Women with Delusional Disorder: Towards a Specialized Approach. Women 1:1, pages 46-59.
Crossref
Bálint Mészáros, Hugo Sámano-Sánchez, Jesús Alvarado-Valverde, Jelena ČalyševaElizabeth Martínez-Pérez, Renato Alves, Denis C. Shields, Manjeet Kumar, Friedrich Rippmann, Lucía B. Chemes & Toby J. Gibson. (2021) Short linear motif candidates in the cell entry system used by SARS-CoV-2 and their potential therapeutic implications. Science Signaling 14:665.
Crossref
S.V. Ivanov & E.I. Voronova. (2021) The newer antipsychotic cariprazine (reagila): perspectives for use in different stages of schizophrenia therapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 121:9, pages 139.
Crossref
Thomas Maestri, David Anderson, Jose Calderon-Abbo, Taylor Waguespack & Margarita Echeverri. (2021) A description of antipsychotic prescribing patterns based on race in the inpatient behavioral health setting. Therapeutic Advances in Psychopharmacology 11, pages 204512532110232.
Crossref
Andreea Teodorescu, Lorena Dima, Mihaela Alexandra Popa, Marius Alexandru Moga, Nicuşor Florin Bîgiu & Petru Ifteni. (2021) Antipsychotics in Postpartum Psychosis. American Journal of Therapeutics 28:3, pages e341-e348.
Crossref
Y. S. Fedorova, P. V. Kulpin, T. V. Kotova, S. V. Denisova & G. V. Beregovykh. Research of psychotropic properties of Xanton-containing plants. Research of psychotropic properties of Xanton-containing plants.
M. Højlund, J. H. Andersen, K. Andersen, C. U. Correll & J. Hallas. (2021) Use of antipsychotics in Denmark 1997–2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses. Epidemiology and Psychiatric Sciences 30.
Crossref
Bushra M. Shah & Susan G. Kornstein. 2021. How Sex and Gender Impact Clinical Practice. How Sex and Gender Impact Clinical Practice 153 169 .
Angelique Egberts, Hava Alan, Gijsbertus Ziere & Francesco U. S. Mattace-Raso. (2020) Antipsychotics and Lorazepam During Delirium: Are We Harming Older Patients? A Real-Life Data Study. Drugs & Aging 38:1, pages 53-62.
Crossref
Mellar P. Davis & Gareth J. Sanger. (2020) The Benefits of Olanzapine in Palliating Symptoms. Current Treatment Options in Oncology 22:1.
Crossref
Michael Kölch. 2020. Psychiatrie und Psychotherapie des Kindes- und Jugendalters. Psychiatrie und Psychotherapie des Kindes- und Jugendalters 1 19 .
Emmanuel Stip, Tahir A. Rizvi, Farah Mustafa, Syed Javaid, Salahdein Aburuz, Nahida Nayaz Ahmed, Karim Abdel Aziz, Danilo Arnone, Aravinthan Subbarayan, Fadwa Al Mugaddam & Gulfaraz Khan. (2020) The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19. Frontiers in Pharmacology 11.
Crossref
Giuseppe Caruso, Margherita Grasso, Annamaria Fidilio, Fabio Tascedda, Filippo Drago & Filippo Caraci. (2020) Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia. Pharmaceuticals 13:12, pages 457.
Crossref
Heidi N. Boyda, Amanzo A. Ho, Lurdes Tse, Ric M. Procyshyn, Jessica W. Y. Yuen, David D. Kim, William G. Honer & Alasdair M. Barr. (2020) Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines. Frontiers in Psychiatry 11.
Crossref
Yue Yang, Xiaoman Li, Ting Wang, Qianqian Guo, Tao Xi & Lufeng Zheng. (2020) Emerging agents that target signaling pathways in cancer stem cells. Journal of Hematology & Oncology 13:1.
Crossref
Francky Teddy Endomba, Aurel T. Tankeu, Jan René Nkeck & Joel Noutakdie Tochie. (2020) Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?. Lipids in Health and Disease 19:1.
Crossref
Marco Solmi, Luca Bodini, Susanna Cocozza, Mary V. Seeman, Eduard Vieta, Elena Dragioti, Andre F. Carvalho & Paolo Fusar-Poli. (2020) Aripiprazole monotherapy as transdiagnostic intervention for the treatment of mental disorders: An umbrella review according to TRANSD criteria. European Neuropsychopharmacology 41, pages 16-27.
Crossref
Jian Jin, Kunxiao Zhang, Fei Dou, Chao Hao, Yifang Zhang, Xudong Cao, Lanchang Gao, Jiaying Xiong, Xin Liu, Bi-Feng Liu, Guisen Zhang & Yin Chen. (2020) Isoquinolinone derivatives as potent CNS multi-receptor D2/5-HT1A/5-HT2A/5-HT6/5-HT7 agents: Synthesis and pharmacological evaluation. European Journal of Medicinal Chemistry 207, pages 112709.
Crossref
Arpita Maitra, Swati Bhattacharyya, Sabyasachi Mukhopadhyay, Asim Kumar Mallick, Supreeti Biswas & Om Prakash Singh. (2020) A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia. Clinical Psychopharmacology and Neuroscience 18:4, pages 587-598.
Crossref
Ulrich Voderholzer, Verena Haas, Christoph U. Correll & Thorsten Körner. (2020) Medical management of eating disorders: an update. Current Opinion in Psychiatry 33:6, pages 542-553.
Crossref
James E. Frampton. (2020) Lumateperone in schizophrenia: a profile of its use. Drugs & Therapy Perspectives 36:11, pages 477-484.
Crossref
Simona Cernea, Lorena Dima, Christoph U. Correll & Peter Manu. (2020) Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. Drugs 80:17, pages 1763-1781.
Crossref
Isadora L. Cortez, Naielly Rodrigues da Silva, Francisco S. Guimarães & Felipe V. Gomes. (2020) Are CB2 Receptors a New Target for Schizophrenia Treatment?. Frontiers in Psychiatry 11.
Crossref
И.Н. Кожанова, И.С. Романова & М.М. Сачек. (2020) Pharmacoeconomic Evaluation of the Use of the Drug Reagila (Cariprazine) for the Treatment of Patients with Schizophrenia with Negative Symptoms. Психиатрия, психотерапия и клиническая психология:3, pages 617-631.
Crossref
László-István Bába, Zsolt Gáll, Melinda Kolcsár, Zsuzsánna Pap, Zoltán V. Varga, Béla Kovács, Beatrix Hack & Imre-Zoltán Kun. (2020) Effect on Body Weight and Adipose Tissue by Cariprazine: A Head-to-Head Comparison Study to Olanzapine and Aripiprazole in Rats. Scientia Pharmaceutica 88:4, pages 50.
Crossref
Aleksandr M. Reznik, Aleksandr L. Arbuzov, Sergey P. Murin & Aleksey V. Pavlichenko. (2020) Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment. Consortium Psychiatricum 1:2, pages 43-51.
Crossref
Igor V. Dorovskikh, Tatyana A. Pavlova & Julia M. Scheidegger. (2020) Cariprazine is a modern antipsychotic with a favorable neuroendocrine profile. Pharmacy Formulas 2:3, pages 58-63.
Crossref
Eoin Mulroy, Bettina Balint & Kailash P Bhatia. (2020) Tardive syndromes. Practical Neurology 20:5, pages 368-376.
Crossref
Kamilla Nyborg Günther, Jytte Banner, Kristian Linnet & Sys Stybe Johansen. (2020) Segmental hair analysis of olanzapine and N-desmethyl-olanzapine in postmortem hair from mentally ill patients by LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 190, pages 113510.
Crossref
Omid Arasteh, Homa Nomani, Hamed Baharara, Seyed A. Sadjadi, Amir H. Mohammadpour, Vahid Ghavami, Thozhukat Sathyapalan & Amirhossein Sahebkar. (2020) Antipsychotic Drugs and Risk of Developing Venous Thromboembolism and Pulmonary Embolism: A Systematic Review and Meta-Analysis. Current Vascular Pharmacology 18:6, pages 632-643.
Crossref
Marcin Siwek, Anna J. Krupa & Anna Wasik. (2020) Lurasidone – pharmacodynamic and pharmacokinetic properties, clinical potential and interaction risk. Pharmacotherapy in Psychiatry and Neurology 36:2, pages 117-134.
Crossref
Xun Zhang, Ming-Jun Qing, Ying-Hua Rao & Yan-Mei Guo. (2020) Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis. Psychiatric Quarterly 91:3, pages 669-679.
Crossref
Marlene Schouby Bock, Oona Nørgaard Van Achter, David Dines, Maria Simonsen Speed, Christoph U Correll, Ole Mors, Søren Dinesen Østergaard & Pernille Kølbæk. (2020) Clinical validation of the self-reported Glasgow Antipsychotic Side-effect Scale using the clinician-rated UKU side-effect scale as gold standard reference. Journal of Psychopharmacology 34:8, pages 820-828.
Crossref
Michael E. Thase. (2020) Charting Sea Changes in Outpatient Pharmacotherapy of Bipolar Disorder. American Journal of Psychiatry 177:8, pages 651-653.
Crossref
Luqi Dai, Qiunan Zuo, Fangying Chen, Lei Chen & Yongchun Shen. (2020) The Association and Influencing Factors between Antipsychotics Exposure and the Risk of VTE and PE: A Systematic Review and Meta-analysis. Current Drug Targets 21:9, pages 930-942.
Crossref
Andrea Botturi, Valentina Ciappolino, Giuseppe Delvecchio, Andrea Boscutti, Bianca Viscardi & Paolo Brambilla. (2020) The Role and the Effect of Magnesium in Mental Disorders: A Systematic Review. Nutrients 12:6, pages 1661.
Crossref
Naielly Rodrigues da Silva, Felipe Villela Gomes, Andreza Buzolin Sonego, Nicole Rodrigues da Silva & Francisco Silveira Guimarães. (2020) Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors. Pharmacological Research 156, pages 104749.
Crossref
Xue-lin Chao, Shu-zhen Jiang, Jian-wen Xiong, Jin-qiong Zhan, Bo Wei, Chun-nuan Chen & Yuan-jian Yang. (2020) Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics. Current Medical Science 40:3, pages 563-569.
Crossref
André F. Carvalho, Marco Solmi, Marcos Sanches, Myrela O. Machado, Brendon Stubbs, Olesya Ajnakina, Chelsea Sherman, Yue Ran Sun, Celina S. Liu, Andre R. Brunoni, Giorgio Pigato, Brisa S. Fernandes, Beatrice Bortolato, Muhammad I. Husain, Elena Dragioti, Joseph Firth, Theodore D. Cosco, Michael Maes, Michael Berk, Krista L. Lanctôt, Eduard Vieta, Diego A. Pizzagalli, Lee Smith, Paolo Fusar-Poli, Paul A. Kurdyak, Michele Fornaro, Jürgen Rehm & Nathan Herrmann. (2020) Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. Translational Psychiatry 10:1.
Crossref
Freja Karuna Hemmingsen Sørup, Robert Eriksson, David Westergaard, Jesper Hallas, Søren Brunak & Stig Ejdrup Andersen. (2020) Sex differences in text-mined possible adverse drug events associated with drugs for psychosis. Journal of Psychopharmacology 34:5, pages 532-539.
Crossref
Lina Fine. (2020) Pharmacologic Approach to Insomnia. Physical Medicine and Rehabilitation Clinics of North America 31:2, pages 255-264.
Crossref
Nicholas Keks, Judith Hope, Darren Schwartz, Harold McLennan, David Copolov & Graham Meadows. (2020) Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. CNS Drugs 34:5, pages 473-507.
Crossref
Indigo Daya, Bridget Hamilton & Cath Roper. (2019) Authentic engagement: A conceptual model for welcoming diverse and challenging consumer and survivor views in mental health research, policy, and practice. International Journal of Mental Health Nursing 29:2, pages 299-311.
Crossref
Lijuan Huo, Guangya Zhang, Xiang-Dong Du, Qiaqiufang Jia, Zheng-Kang Qian, Dachun Chen, Meihong Xiu, Fengchun Wu, Jair C. Soares, Xingbing Huang, Ryan M. Cassidy, Yuping Ning & Xiang Yang Zhang. (2020) The prevalence, risk factors and clinical correlates of diabetes mellitus in Chinese patients with schizophrenia. Schizophrenia Research 218, pages 262-266.
Crossref
Fabian Wagner & Armin Kalenka. (2020) Full Recovery After Unprecedently High Levels of Deliberate Amisulpride Near-Fatal Intoxication. Journal of Clinical Psychopharmacology 40:2, pages 210-211.
Crossref
Francesco Rotella, Emanuele Cassioli, Enrico Calderani, Lisa Lazzeretti, Benedetta Ragghianti, Valdo Ricca & Edoardo Mannucci. (2020) Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. European Neuropsychopharmacology 32, pages 56-65.
Crossref
Jens Bohlken, Marcel Konrad & Karel Kostev. (2020) Adherence to neuroleptic treatment in psychiatric practices: A retrospective study of 55 practices with more than 5000 bipolar and schizophrenic patients in Germany. Psychiatry Research 284, pages 112758.
Crossref
Indrani Poddar, Patrick M. Callahan, Caterina M. Hernandez, Anilkumar Pillai, Xiangkun Yang, Michael G. Bartlett & Alvin V. TerryJrJr. (2020) Chronic oral treatment with risperidone impairs recognition memory and alters brain-derived neurotrophic factor and related signaling molecules in rats. Pharmacology Biochemistry and Behavior 189, pages 172853.
Crossref
Robyn P. Thom, Christopher J. Keary, Jessica L. Waxler, Barbara R. Pober & Christopher J. McDougle. (2019) Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series. Journal of Autism and Developmental Disorders 50:2, pages 676-682.
Crossref
Christian Schmidt-Kraepelin, Sandra Feyerabend, Christina Engelke, Mathias Riesbeck, Eva Meisenzahl-Lechner, Wolfgang Gaebel, Pablo-Emilio Verde, Henrike Kolbe, Christoph U. Correll, Stefan Leucht, Stephan Heres, Michael Kluge, Christian Makiol, Andrea Neff, Christina Lange, Susanne Englisch, Mathias Zink, Berthold Langguth, Timm Poeppl, Dirk Reske, Euphrosyne Gouzoulis-Mayfrank, Gerhard Gründer, Alkomiet Hasan, Anke Brockhaus-Dumke, Markus Jäger, Jessica Baumgärtner, Thomas Wobrock & Joachim Cordes. (2019) A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. European Archives of Psychiatry and Clinical Neuroscience 270:1, pages 83-94.
Crossref
Shaina Musco, Vivian McAllister & Ian Caudle. (2020) Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment. Therapeutic Advances in Psychopharmacology 10, pages 204512532093757.
Crossref
E. Clapham, R. Bodén, J. Reutfors, T. Svensson, D. Ramcharran, H. Qiu, H. Kieler & S. Bahmanyar. (2019) Exposure to risperidone versus other antipsychotics and risk of osteoporosis‐related fractures: a population‐based study. Acta Psychiatrica Scandinavica 141:1, pages 74-83.
Crossref
Yvonne van der Zalm, Fabian Termorshuizen, Iris E. Sommer & Jean-Paul Selten. (2020) Use of cardiovascular and antidiabetic drugs before and after starting with clozapine versus other antipsychotic drugs. International Clinical Psychopharmacology 35:1, pages 36-41.
Crossref
Marco Solmi, Ai Koyanagi, Trevor Thompson, Michele Fornaro, Christoph U Correll & Nicola Veronese. (2019) Network analysis of the relationship between depressive symptoms, demographics, nutrition, quality of life and medical condition factors in the Osteoarthritis Initiative database cohort of elderly North-American adults with or at risk for osteoarthritis. Epidemiology and Psychiatric Sciences 29.
Crossref
Yoav Domany & Mark Weiser. (2020) Insights into metabolic dysregulations associated with antipsychotics. The Lancet Psychiatry 7:1, pages 6-7.
Crossref
C. U. Correll. (2020) Pharmakotherapie der SchizophreniePharmacotherapy of schizophrenia. Der Nervenarzt 91:1, pages 34-42.
Crossref
Mary V. Seeman. 2020. Mental Health and Illness of Women. Mental Health and Illness of Women 231 258 .
Amy S. Aloysi & Eileen H. Callahan. 2020. Geriatric Practice. Geriatric Practice 223 236 .
Xinyu Fang, Yan Chen, Yewei Wang, Juanjuan Ren & Chen Zhang. (2019) Depressive symptoms in schizophrenia patients: A possible relationship between SIRT1 and BDNF. Progress in Neuro-Psychopharmacology and Biological Psychiatry 95, pages 109673.
Crossref
Marjaana Koponen, Piia Lavikainen, Heidi Taipale, Antti Tanskanen, Jari Tiihonen, Sirpa Hartikainen & Anna-Maija Tolppanen. (2019) Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease. Journal of the American Medical Directors Association 20:12, pages 1488-1494.e3.
Crossref
Afzal Javed, Holger Arthur, Logos Curtis, Lars Hansen & Sofia Pappa. (2019) Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. Neurology and Therapy 8:2, pages 215-230.
Crossref
Gregory Purcell, Jane McCartney & Shirley-Anne Boschmans. (2019) Documentation of antipsychotic-related adverse drug reactions: An educational intervention. South African Journal of Psychiatry 25.
Crossref
Artur Świerczek, Agnieszka Jankowska, Grażyna Chłoń-Rzepa, Maciej Pawłowski & Elżbieta Wyska. (2019) Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia. Current Drug Targets 20:16, pages 1652-1669.
Crossref
Jie Jia, Jun Shen, Fei-Hu Liu, Hei Kiu Wong, Xin-Jing Yang, Qiang-Ju Wu, Hui Zhang, Hua-Ning Wang, Qing-Rong Tan & Zhang-Jin Zhang. (2019) Effectiveness of Electroacupuncture and Electroconvulsive Therapy as Additional Treatment in Hospitalized Patients With Schizophrenia: A Retrospective Controlled Study. Frontiers in Psychology 10.
Crossref
R. Pandit, D. Cianci, S. E. Hark, I. Winter‐van Rossum, B. H. Ebdrup, B. V. Broberg, M. P. Garcia‐Portilla, J. Bobes, C. H. Vinkers, R. S. Kahn, S. Guloksuz, A. D. R. Huitema & J. J. Luykx. (2019) Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPT iMi SE cohort) . Acta Psychiatrica Scandinavica 140:3, pages 283-290.
Crossref
D. Papola, G. Ostuzzi, C. Gastaldon, G. P. Morgano, E. Dragioti, A. F. Carvalho, P. Fusar‐Poli, C. U. Correll, M. Solmi & C. Barbui. (2019) Antipsychotic use and risk of life‐threatening medical events: umbrella review of observational studies. Acta Psychiatrica Scandinavica 140:3, pages 227-243.
Crossref
Filippo Corponi, Chiara Fabbri, Istvan Bitter, Stuart Montgomery, Eduard Vieta, Siegfried Kasper, Stefano Pallanti & Alessandro Serretti. (2019) Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology 29:9, pages 971-985.
Crossref
Rebecca S. Hofford, Scott J. Russo & Drew D. Kiraly. (2018) Neuroimmune mechanisms of psychostimulant and opioid use disorders. European Journal of Neuroscience 50:3, pages 2562-2573.
Crossref
Amanda Krogmann, Luisa Peters, Laura von Hardenberg, Katja Bödeker, Viktor B. Nöhles & Christoph U. Correll. (2019) Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectrums 24:S1, pages 38-69.
Crossref

Displaying 200 of 246 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.